Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIPO-5 HIV Vaccine in Healthy Volunteers
NCT00121758Phase 2Completed
- Sponsor
- ANRS
- Start
- Sep 2004
- Primary completion
- Nov 2007
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing LIPO-5 with Placebo (2 arms). Primary endpoint: Percentage of patients with CD8 immune response on ELISPOT IFN-gamma at 48 weeks. Started Sep 2004; status: completed.
02
Drugs
LIPO-5
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00121758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121758.